Perspective Comprehensive Prescribing Data OPDIVO® (nivolumab) is indicated with the treatment of Grownup patients with classical Hodgkin lymphoma (cHL) which has relapsed or progressed right after autologous hematopoietic stem cell transplantation (HSCT) and brentuximab vedotin or following